- Home
- KOSS vs BOLD Comparison
KOSS vs BOLD Comparison
Compare KOSS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOSS
- BOLD
- Stock Information
- Founded
- KOSS 1953
- BOLD 2018
- Country
- KOSS United States
- BOLD United States
- Employees
- KOSS N/A
- BOLD N/A
- Industry
- KOSS Consumer Electronics/Appliances
- BOLD
- Sector
- KOSS Consumer Staples
- BOLD
- Exchange
- KOSS Nasdaq
- BOLD Nasdaq
- Market Cap
- KOSS 53.6M
- BOLD 25.5M
- IPO Year
- KOSS N/A
- BOLD 2024
- Fundamental
- Price
- KOSS $5.21
- BOLD $1.41
- Analyst Decision
- KOSS
- BOLD Buy
- Analyst Count
- KOSS 0
- BOLD 4
- Target Price
- KOSS N/A
- BOLD $4.00
- AVG Volume (30 Days)
- KOSS 42.7K
- BOLD 185.5K
- Earning Date
- KOSS 10-28-2025
- BOLD 11-06-2025
- Dividend Yield
- KOSS N/A
- BOLD N/A
- EPS Growth
- KOSS N/A
- BOLD N/A
- EPS
- KOSS N/A
- BOLD N/A
- Revenue
- KOSS $12,624,170.00
- BOLD N/A
- Revenue This Year
- KOSS N/A
- BOLD N/A
- Revenue Next Year
- KOSS N/A
- BOLD N/A
- P/E Ratio
- KOSS N/A
- BOLD N/A
- Revenue Growth
- KOSS 2.93
- BOLD N/A
- 52 Week Low
- KOSS $4.00
- BOLD $1.00
- 52 Week High
- KOSS $8.59
- BOLD $3.75
- Technical
- Relative Strength Index (RSI)
- KOSS 45.32
- BOLD 80.01
- Support Level
- KOSS $4.82
- BOLD $1.23
- Resistance Level
- KOSS $5.70
- BOLD $1.44
- Average True Range (ATR)
- KOSS 0.22
- BOLD 0.08
- MACD
- KOSS 0.03
- BOLD 0.02
- Stochastic Oscillator
- KOSS 42.29
- BOLD 82.75
About KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.